Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women

Journal of Clinical Virology

Volumn 41, Issue 4, 2008, Pages 255-263

  Operskalski, Eva A ^a   Mack, Wendy J ^a   Strickler, Howard D ^b   French, Audrey L ^c   Augenbraun, Michael ^d   Tien, Phyllis C ^e   Villacres, Maria C ^a   Spencer, LaShonda Y ^a   DeGiacomo, Marina ^a   Kovacs, Andrea ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Department of Ambulatory and Community Health   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis C; Hepatitis C RNA levels; Hepatitis C viremia; HIV hepatitis C virus co infection

Indexed keywords

AMPHETAMINE; ANTIRETROVIRUS AGENT; CANNABIS; COCAINE; DIAMORPHINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGIC FACTOR; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GROUPS BY AGE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MIXED INFECTION; MONOTHERAPY; PRIORITY JOURNAL; SMOKING; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ADULT; AGE FACTORS; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MIDDLE AGED; PLASMA; RISK FACTORS; RNA, VIRAL; SEX FACTORS; SMOKING; SUBSTANCE-RELATED DISORDERS; UNITED STATES; VIRAL LOAD; VIREMIA;

EID: 40849114508     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2007.08.021     Document Type: Article

References (45)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
2. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006) 705-714
3. Bacon M.C., von Wyl V., Alden C., et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 12 (2005) 1013-1019
4. Baldwin G.C., Tashkin D.P., Buckley D.M., et al. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 156 (1997) 1606-1613
5. Brau N., Bini E.J., Currie S., et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 13 (2006) 242-249
6. Busch M.P., Glynn S.A., Stramer S.L., et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 46 (2006) 469-475
7. Chao C.C., Hu S., Molitor T.W., et al. Morphine potentiates transforming growth factor-beta release from human peripheral mononuclear cell cultures. J Pharmacol Exp Ther 262 (1992) 19-24
8. Chao C.C., Molitor T.W., Close K., Hu S., and Peterson P.K. Morphine inhibits the release of tumor necrosis factor in human peripheral mononuclear cell cultures. Int J Immunopharmacol 15 (1993) 447-453
9. Chayama K., Kobayashi M., Tsubota A., et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol 22 (1995) 431-439
10. Cribier B., Rey D., Schmitt C., Lang J.M., Kim A., and Stoll-Keller F. High hepatitis C viremia and impaired antibody response in patients co-infected with HIV. AIDS 9 (1995) 1131-1136
11. Daar E.S., Lynn H., Donfield S., et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 26 (2001) 466-472
12. Dieterich D.T. Hepatitis C virus and human immunodeficiency virus: clinical issues in co-infection. Am J Med 107 (1999) 79S-84S
13. Fishbein D.A., Lo Y., Netski D., Thomas D.L., and Klein R.S. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J Acquir Immune Defic Syndr 41 (2006) 471-476
14. Friedman H., Newton C., and Klein T.W. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 16 (2003) 209-219
15. Gordon S.C., Dailey P.J., Silverman A.L., et al. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 28 (1998) 1702-1706
16. Hezode C., Lonjon I., Roudot-Thoraval F., et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 52 (2003) 126-129
17. Hezode C., Roudot-Thoraval F., Nguyen S., et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42 (2005) 63-71
18. Hisada M., O'Brien T.R., Rosenberg P.S., Goedert J.J., and for the Multicenter Hemophilia Cohort Study. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. J Infect Dis 181 (2000) 1475-1478
19. Jardi R., Rodriguez F., Buti M., et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promotor mutations on viral replicative interference. Hepatology 34 (2001) 404-410
20. Joy J.E., Watson S.J., and Benson J.A. Marijuana and medicine: assessing the science base (1999), National Academy Press, Washington, DC
21. McAllister-Sistilli C.G., Caggiula A.R., Knopf S., et al. The effects of nicotine on the immune system. Psychoneuroendocrinology 23 (1998) 175-187
22. Minkoff H., Feldman J.G., Strickler H.D., et al. Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women. J Infect Dis 189 (2004) 1821-1828
23. Mohsen A.H., Easterbrook P., Taylor C.B., and Norris S. Hepatitis C and HIV-1 co-infection. Gut 51 (2002) 601-608
24. Nair M.P., Kronfol Z.A., and Schwartz S.A. Effects of alcohol and nicotine on cytotoxic functions of human lymphocytes. Clin Immunol Immunopathol 54 (1990) 395-409
25. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. June 10-12, 2002. Available at: http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm.
26. Ouyang Y., Virasch N., Hao P., et al. Suppression of human IL-1β, IL-2, IFN-γ, and TNF-α production by cigarette smoke extracts. J Allergy Clin Immunol 106 (2000) 280-287
27. Pessione F., Ramond M.J., Njapoum C., et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 34 (2001) 121-125
28. Peterson P.K., Sharp B., Gekker G., Brummitt C., and Keane W.F. Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest 80 (1987) 824-831
29. Piasecki B.A., Lewis J.D., Reddy K.R., et al. Influence of alcohol use, race, and viral co-infections on spontaneous HCV clearance in a US veteran population. Hepatology 40 (2004) 892-899
30. Raimondo G., Brunetto M.R., Pontisso P., et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. Hepatology 43 (2006) 100-107
31. Roth M.D., Tashkin D.P., Choi R., et al. Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis 185 (2002) 701-705
32. Sagnelli E., Coppola N., Marrocco C., et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol 35 (2006) 317-320
33. Sherman K.E., O'Brien J., Gutierrez A.G., et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 31 (1993) 2679-2682
34. Thio C.L., Thomas D.L., Goedert J.J., et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 184 (2001) 16-21
35. Thomas D.L., Astemborski J., Rai R.M., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284 (2000) 450-456
36. Thomas D.L., Astemborski J., Vlahov D., et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 181 (2000) 844-851
37. Thomas D.L., Rich J.D., Schuman P., et al. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis 183 (2001) 973-976
38. Thomas D.L., and Seeff L.B. Natural history of hepatitis C. Clin Liver Dis 9 (2005) 383-398
39. Thomas D.L., Shih J.W., Alter H.J., et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 174 (1996) 690-695
40. Thomas D.L., Villano S.A., Riester K.A., et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 177 (1998) 1480-1488
41. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Eng J Med 351 (2004) 438-450
42. Villano S.A., Vlahov D., Nelson K.E., Cohn S., and Thomas D.L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29 (1999) 908-914
43. Winnock M., Salmon-Ceron D., Dabis F., and Chene G. Interaction between HIV-1 and HCV infections: towards a new entity?. J Antimicrob Chemother 53 (2004) 936-946
44. Yeo A.E.T., Ghany M., Conry-Cantilena C., et al. Stability of HCV-RNA level and its lack of correlation with disease severity in a symptomatic chronic hepatitis C virus carriers. J Viral Hepat 8 (2001) 256-263
45. Zhang M., Rosenberg P.S., Brown D.L., et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 107 (2006) 892-897